New approach could reduce therapy resistance in pancreatic carcinoma…

medicine

Friday March 31, 2023

Stuttgart – Therapy resistance that is particularly common in ductal adenocarcinoma of the pancreas (PDAC) could be prevented or reversed. This is the result of researchers led by the Robert Bosch Center for Tumor Diseases in Stuttgart using in vitro and in vivo models of resistant PDAC. The study was published in Gut (2023; DOI: 10.1136/gutjnl-2022-328154). The addition of an active ingredient may be sufficient to…